Search research articles
Contact Us
Filters
Showing results (81-90 of 283) with videos related to
Page
of 29
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 14, 2017
Preclinical Development of CD38-Targeted [<sup>89</sup>Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma
Anchal Ghai, Dolonchampa Maji, Nicholas Cho, et al.
Haematologica
|
August 13, 2013
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
David Siegel, Thomas Martin, Ajay Nooka, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 5, 2026
Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection
Samer Al Hadidi, Caitlin Costello, Luciano J Costa, et al.
British Journal of Haematology
|
September 27, 2003
Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity
Rizwana Chohan, Ravi Vij, Douglas Adkins, et al.
Blood
|
May 10, 2017
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
Thomas Martin, Rachid Baz, Don M Benson, et al.
Cancer Control : Journal of the Moffitt Cancer Center
|
December 22, 2025
Convenience Versus Continuity: A Pilot Study of Care Transfer to a Satellite Clinic for Patients With Plasma Cell Dyscrasias
Angela M Vickroy, Margaret Kavanaugh, Jordan Smith, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 23, 2016
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study
Jesus Berdeja, Sundar Jagannath, Jeffrey Zonder, et al.
Theranostics
|
October 3, 2025
Chemo-RaST with bortezomib inhibits multiple myeloma relapse
Anchal Ghai, Alexander Zheleznyak, Christopher Egbulefu, et al.
Leukemia
|
January 22, 2021
Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy
Kinan Alhallak, Jennifer Sun, Katherine Wasden, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 5, 2023
Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone
Alexa J Loncharich, Mark A Fiala, Michael J Slade, et al.
Page
of 29
Search research articles
Search
Showing results (81-90 of 283) with videos related to
Sort By:
Page
of 29
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 14, 2017
Preclinical Development of CD38-Targeted [<sup>89</sup>Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma
Anchal Ghai, Dolonchampa Maji, Nicholas Cho, et al.
Haematologica
|
August 13, 2013
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
David Siegel, Thomas Martin, Ajay Nooka, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 5, 2026
Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection
Samer Al Hadidi, Caitlin Costello, Luciano J Costa, et al.
British Journal of Haematology
|
September 27, 2003
Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity
Rizwana Chohan, Ravi Vij, Douglas Adkins, et al.
Blood
|
May 10, 2017
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
Thomas Martin, Rachid Baz, Don M Benson, et al.
Cancer Control : Journal of the Moffitt Cancer Center
|
December 22, 2025
Convenience Versus Continuity: A Pilot Study of Care Transfer to a Satellite Clinic for Patients With Plasma Cell Dyscrasias
Angela M Vickroy, Margaret Kavanaugh, Jordan Smith, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 23, 2016
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study
Jesus Berdeja, Sundar Jagannath, Jeffrey Zonder, et al.
Theranostics
|
October 3, 2025
Chemo-RaST with bortezomib inhibits multiple myeloma relapse
Anchal Ghai, Alexander Zheleznyak, Christopher Egbulefu, et al.
Leukemia
|
January 22, 2021
Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy
Kinan Alhallak, Jennifer Sun, Katherine Wasden, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 5, 2023
Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone
Alexa J Loncharich, Mark A Fiala, Michael J Slade, et al.
Page
of 29